

**ASX Announcement**

27 August 2020

**Lapse of Performance Rights**

The Directors of **Mediland Pharm Limited** ("**Mediland**" or the "**Company**") advises that of the 13,300,000 Performance Rights granted in FY2019, a total of 4,433,333 Performance Rights (ASX Code: MPHAC) under the Long-Term Incentive Plan (LTIP) have lapsed or been forfeited:

Total remaining performance rights on issue are as follows:

<b>ASX CODE</b>	<b>Description</b>
MPHAC	8,866,667 FY 2019 Performance Rights

**Authorised for release by the Company Secretary of Mediland Pharm Limited.**

**\_ENDS\_**

**IR Enquiries**

[ir@medilandpharm.com.au](mailto:ir@medilandpharm.com.au)

**Company enquiries**

[yesh.mudaliar@medilandpharm.com.au](mailto:yesh.mudaliar@medilandpharm.com.au)

**About Mediland Pharm**

Mediland Pharm is a leading retailer of cosmetics, jewellery, health, well-being, and wool products, serving the inbound Chinese tourism market in Australia and New Zealand. The Company operates three retail stores located in Australia (Sydney, Melbourne, and the Gold Coast) and one in Auckland, New Zealand. Mediland partners with leading travel agents and wholesale tour operators to generate sales through exclusive customer shopping agreements.